View Post

I-Mab Announces IND Approval for Its Proprietary TJC4, A Potentially Differentiated CD47 Antibody, to Initiate Clinical Trials in China

In Clinical Trials by Barbara Jacoby

Source: I-MAB Pharma From: prnewswire.com I-Mab Biopharma (“I-Mab”), a clinical stage biotech company exclusively focusing on discovery and development of innovative biologics in immuno-oncology and autoimmune diseases, announces that the National Medical Products Administration (NMPA) has approved its investigational new drug (IND) application for TJC4, a differentiated fully human CD47 monoclonal antibody internally developed for the treatment of advanced malignant …

View Post

Lessons Learned in My Search for a Metastatic Cancer Clinical Trial

In Clinical Trials by Barbara Jacoby

By: Sarah DeBord From: curetoday.com Sarah DeBord was diagnosed with metastatic colon cancer at age 34. In the years since, she has turned her diagnosis into a calling, and become an advocate for other young adults diagnosed with colorectal cancer and parents with young families facing cancer. She works as a communications and program manager for the Minneapolis-based Colon Cancer …

View Post

Backed by Dana-Farber research, FDA approves new drug combination for treating advanced kidney cancer

In In The News by Barbara Jacoby

Source: dana-farber.org From: Redington Life Sciences News An immunotherapy drug combination whose clinical testing was co-led by Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, has become a standard first-line therapy for patients with metastatic kidney cancer. The drug combination of the immunotherapy drug avelumab (BAVENCIO) plus axitinib (INLYTA), a VEGF targeted agent, was approved today by the U.S. Food …

View Post

Phase III Shows Benefit With Olaparib in Platinum-Sensitive BRCA+ Relapsed Ovarian Cancer

In Clinical Trials by Barbara Jacoby

By: Danielle Ternyila From: targetedonc.com According to topline findings from the multicenter, open-label, phase III SOLO3 trial, the overall objective response rate (ORR) was 72% with single-agent olaparib (Lynparza) versus 51% with chemotherapy in patients with platinum-sensitive, relapsed, germline BRCA-mutant ovarian cancer who were previously treated with at least 2 chemotherapy regimens. Further, in patients with only 2 prior lines …

View Post

Immutep Completes Patient Enrolment of the AIPAC Phase IIb Clinical Trial in Metastatic Breast Cancer

In Clinical Trials by Barbara Jacoby

Source: GLOBE NEWSWIRE From: yahoo.com 226 patients with metastatic breast cancer have been enrolled in the AIPAC study Combination of eftilagimod alpha, an antigen presenting cell (APC) activator, administered in combination with chemotherapy is designed to boost the T-cell immune responses against tumours Read-out of progression-free survival (PFS) primary endpoint expected to occur in Q1 of calendar year 2020 Immutep …

View Post

Clinical trial underscores promise of immunotherapy, in combination with second drug, for ovarian cancer

In Clinical Trials by Barbara Jacoby

From: dana-farber.org A combination of an immunotherapy drug and a DNA repair-blocking agent can be significantly more effective than either drug alone in women with hard-to-treat ovarian cancer, a phase I/II clinical trial led by Dana-Farber Cancer Institute researchers indicates. The trial, known as TOPACIO/Keynote-162, offers compelling evidence that immunotherapies, which rarely have an impact against ovarian cancer as single …

View Post

G1 Therapeutics Announces Updated Results from Phase 2 Trial of Trilaciclib in Combination with Chemotherapy

In Clinical Trials by Barbara Jacoby

Source: G1 Therapeutics From: globenewswire.com G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced preliminary overall survival (OS) results from a randomized Phase 2 trial which demonstrated that women with metastatic triple-negative breast cancer (mTNBC) lived significantly longer when receiving trilaciclib and chemotherapy compared with women receiving chemotherapy alone. Detailed data from this trial will be presented at …

View Post

Pancreatic cancer patient in partial remission after experimental drug treatment

In Clinical Trials by Barbara Jacoby

By: Ronda Wendler From: mdanderson.org Allison Lippman was 30 years old when she was diagnosed with stage 4 pancreatic cancer. A new drug that targets her cancer’s genetic mutation has shrunk her tumors in half. Just before she was diagnosed with pancreatic cancer, Allison Lippman was on top of the world. She’d just celebrated her 30th birthday, been promoted at …

View Post

Todos Medical Announces Positive Clinical Trial Data for Breast Cancer Blood Test TM-B1 in Dense Breasts

In Clinical Trials by Barbara Jacoby

Source: Todos Medical Ltd. From: .globenewswire.com Todos Medical Ltd. (OTCQB: TOMDF) (http://www.Todosmedical.com) today announced positive results from a clinical trial completed at CGH Hospital in Singapore. The trial related to the Company’s proprietary TM-B1 Assay for breast cancer screening, initiated in July 2016. The trial was prospective, two arms, enrolling 257 female patients over a period of over 2 years. …

View Post

ASCO 2019: Test All Triple Negative Breast Cancer Patients for PD-L1

In Clinical Trials by Barbara Jacoby

From: physiciansweekly.com Latest analysis from IMpassion trial confirms need for testing One of the repeated themes of the American Society of Clinical Oncology meeting here was the need for baseline testing of any target that can inform truly precision use of targeted therapies, and that message came through loud and clear during an oral abstract session devoted to treatment of …